Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03861793
Brief Title: A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

First Submitted : February 25, 2019
First Submitted that Met QC Criteria : March 1, 2019
First Posted : March 4, 2019

Last Update Submitted that Met QC Criteria : March 5, 2021
Last Update Posted : March 8, 2021